chrisvoncsefalvay/vaers-outcomes huggingface dataset:
both my hands started to get itchy, burning; both my hands started to get itchy, burning; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 54 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administration date 21Jan2021 15:15 (Lot number: EL0142) at the age of 54 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "high blood pressure" (unspecified if ongoing); "DMII" (unspecified if ongoing); "High cholesterol" (unspecified if ongoing); "covid" (unspecified if ongoing), notes: If covid prior vaccination: Yes. The patient took concomitant medications. The following information was reported: PRURITUS (non-serious), BURNING SENSATION (non-serious) all with onset 08Dec2021 07:00, outcome "recovered" and all described as "both my hands started to get itchy, burning". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of pruritus, burning sensation.  Additional information: At Public Health Clinic/Veterans Administration facility the vaccine was administered. No other vaccine was administered in four weeks. Other medications were administered in two weeks. The day after having the Booster both her hands started to get itchy, burning. She took Benadryl to get relief. Patient had covid prior vaccination. Patient had covid tested post vaccination. Patient had known allergies.  Follow-up attempts are completed. No further information is expected.
The back of my head and neck were very swollen and sore since I received the vaccine. My fingers and fingertips have been experiencing extreme pain, numbness, and tingling since I received the vaccine. My right hand and arm have been having burning pain, numbness and tingling. The pinky finger on my right hand has hurt the worst and the pain hasn?t gone away.
3- 4 days after Moderna booster dose c/o pressure in left side of chest- racing heart- worse at night when laying flat- petichiae spots on tops of feet
This case was reported by a nurse via sales rep and described the occurrence of injection site pain in a male patient who received BEXSERO for prophylaxis. On an unknown date, the patient received the 1st dose of BEXSERO. On an unknown date, immediately after receiving BEXSERO, the patient experienced injection site pain. On an unknown date, the outcome of the injection site pain was unknown. It was unknown if the reporter considered the injection site pain to be related to BEXSERO. Additional details were reported as follows: This case was reported by a nurse who gave the 2nd injection of BEXSERO. The age at vaccination was not reported. Few years before the date of reporting, the patient received a dose of BEXSERO. The patient reported that, the injection was painful and was not able to dress himself. The nurse gave consent to follow up. For tolerance after 2nd dose of SHINGRIX, refer case US2018199518.
Pain in the left arm from area were flu shot was given into the muscle and part way down to the elbow. Can't move left arm w/o pain. Still very sore and tender on the spot where shot was given.
feeling some aches after the second vaccine, but she attributed to the vaccine instead of being off xeljanz; This is a spontaneous report from a contactable consumer(Patient) from a Pfizer sponsored. A 75-years-old female patient received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, solution for injection, Lot Number: unknown), via an unspecified route of route of administration in Feb2021 (age at vaccination was 75 years) as dose 2, single for COVID-19 immunization and tofacitinib citrate (XELJANZ XR) ongoing since 14Jan2021 at dose of 11 mg once daily via oral route of administration for an unspecified indication. Medical history and concomitant medications were not reported. Historical vaccine included bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, solution for injection, Lot number: unknown) via an unspecified route of administration on unspecified date as dose 1, single for COVID-19 immunization. On an unspecified date, the patient feeling some aches after the second vaccine, but she attributed to the vaccine instead of being off xeljanz. The patient was feeling great with xeljanz. Being on xeljanz now consistently after receiving her covid vaccine in February. md is aware. She also reported being off xeljanz for 8 days when she got her second covid vaccine. Outcome of the event was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
flu like systems; This case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in an unspecified number of patients who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced influenza-like symptoms. On an unknown date, the outcome of the influenza-like symptoms was unknown.   It was unknown if the reporter considered the influenza-like symptoms to be related to Shingrix.  Additional information was provided as follows: The age at vaccination was not applicable for this report. The reporter stated that, his/her friends experienced flu like symptoms after vaccination.  The reporter was yet to receive the vaccine and was trying to plan a day around it. The reporter wanted to know that how long after receiving the first vaccine might the side effects start and for how long after vaccination might he/she experience side effects. The reporter was advised to refer to his/her health care provider.
This spontaneous report as received from a physician refers to 3 patients of unknown age. On unknown dates, the patients were vaccinated with a dose of ZOSTAVAX (dose, route and lot number not reported). No other co-suspects were reported. No concomitant medications were reported. On unknown dates, the patients developed what was described as shingles outbreak localized to the injection site after receiving ZOSTAVAX. No treatment information was reported. The outcome of shingles outbreak localized to the injection site after receiving ZOSTAVAX was unknown. The relatedness for shingles outbreak localized to the injection site after receiving ZOSTAVAX was unknown for ZOSTAVAX. Additional information has been requested.
Pain at previous surgical site -- painful to the touch.  Severe joint pain at site of fracture.
Swollen glands under right arm (same arm as vaccinated); This is a spontaneous report from a contactable other healthcare professional, the patient. A 70-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 11Feb2021 at 12:00 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. The patient's medical history was reported as not applicable. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included gabapentin (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 21Jan2021 at 12:00 (at the age of 70-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in 2021, the patient experienced swollen glands under right arm (same arm as vaccinated). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen glands under right arm was recovered on unknown date in 2021.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
A few days following my second Pfizer shot, the tinnitus in my left ear made a very noticeable spike. I've had tinnitus in that ear since I was a teen following a really bad cold but it was low enough that I only really noticed it in a silent environment. Now though I can easily detect it at a normal room volume and it sometimes come with a slight pain or pressure in the ear canal. When consulting with an ENT specialist, their guess is that the vaccine caused a slight inflammation that sometimes happens with vaccines and they just advised me to do what I can to adjust my life accordingly. Everything otherwise looked fine.
Client received 3 immunizations in this order: Tdap and MCV4 into right deltoid and HPV into left deltoid.  After the 3rd immune was administered client started to slump in her chair and all color drained from her face.  She was assisted to a lying position on the floor.  She was breathing but did not respond to questions asked for about 15-20 seconds.  She then stated that she felt like she had to throw up.  She was able to follow the command to breath deeply and within a few minutes the coloring started to return to her face.  She did not throw up. She remained in a supine position for about 15 minutes and then a sitting position for another 15 minutes before she was released.  She could not remember anything about the experience except for someone helping her to the floor.  She asked her guardian if she had fallen asleep.
Emp came to Employee Health c/o trouble breathing. Escorted to Emergency Room. Triaged, evaluated approx. 30 min later at 1:30pm. Epi 0.3mg  IM admin. Observed for 2 hours, sent home.
headache worsening over 24 hours, body aches, chills, and fever on day 2. Sore and itchy injection site, headaches on day 3.
Muscle pain Nausea  Muscle spasms  Fatigue Weakness  Nerve pain
Muscle pain, sweating, chills within 8 hours, then tendon weakness, pulled muscle,  and increased inflammation in joints starting one week after vaccination and still continuing after one month.  Injection site pain continues even one month after vaccination
p/vax arm began to swell & itch & became red;tx w/advil, DPH & compress;
Fever and chills. Take Tylenol 600mg every 6 hrs. Warm compress if any swelling.
Fatigue and achiness about 6 hours after receiving injection. Developed chills, muscle aches and fever, 99.3-100.4, 8-9 hours after injection. Fever was gone by 7:30AM the next morning (11 hours after injection), however continued to have muscle soreness and increased fatigue for the remainder of the day
Fast heart rate; Breathing difficulties; Local reaction; This is a spontaneous report from a contactable consumer (patient). A 41-years-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot Number: En6206), via an unspecified route of administration, administered in Arm Left on 18Mar2021 (at the age of 41-years-old) as dose 1, single for covid-19 immunization at public health clinic/veterans administration facility. Medical history included known allergies to latex, adhesives, buckwheat from an unknown date and unknown if ongoing. The patient previously took lisinopril and motrin [ibuprofen] and experienced allergies. Concomitant medications (other medications in two weeks) included allergy shots. Could contact her for other medical history and for other medications in two weeks. No other vaccine in four weeks. No COVID prior vaccination and no COVID tested post vaccination. On 18Mar2021, after first shot the patient had fast heart rate, breathing difficulties (throughout evening of shot), and local reaction that she still has 6 weeks later with use of topical steroids. The adverse events resulted in doctor or other healthcare professional office/clinic visit. The patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot Number: Er8727) via an unspecified route of administration, administered in Arm Right on 09Apr2021 as dose 2, single for covid-19 immunization. The patient was treated with topical steroid. The outcome of all events was not recovered.  No follow-up attempts are possible. No further information is expected.
Given vaccines 6/3/09, started with fevers to 104-105 on 6/4/09, seen in clinic 6/5/09 with fever to 104.4, no S/S URI, UA dip (-). F/U call 6/6/09 fever resolved, now 99: today started with congested cough.
1st dose March2019, 2nd never; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received the first dose of Shingrix in March 2019).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 26-SEP-2022 Reporter's Comment: The reporter reported that, never received the 2nd dose of Shingrix.  The reporter wanted to know if needed to restart the series. The reporter did not consent to follow-up.  Additional Supportive Information: Till the time of reporting, the patient did not receive the 2nd dose of Shingrix, which led to incomplete course of vaccination.
PATIENT EXPERIANCE SWELLING THE NEXT DAY WITH HEAD ACHE, FOLLOWED BY DISCOLORIZATION OF THE ENTORE UPER ARM FROM THE SITE IF INJECTION TO LOWER YELBOW WITH CLOTS.
The patient had no issues, the only problem was she isn't 65 and she didn't need the high dose.
Child age 10 was administered Pfizer booster for ages 12+ as their 2nd COVID booster shot. Client parent called and informed of incident when occurrence was noticed. No adverse reactions noted.
Breakthrough case admission after 3 vaccines Moderna 3/18/21 Lot# 023M20A;  Moderna 4/15/21 Lot# 010M20A;  Moderna 11/16/21 Lot# 017F21A
No additional AE reported; a dose of VAQTA had been inadvertently administered after its labeled expiry date; This spontaneous report was received from a certified medical assistant and refers to a 20-month-old patient of unknown gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On 22-APR-2021, the patient was inadvertently vaccinated with expired hepatitis A vaccine, inactivated (VAQTA) prefilled syringe (PFS) 25U/0.5 milliliter, lot # S037576, expiration date 10-APR-2021 (route of administration and anatomical location were not provided) for prophylaxis. There were no prior temperature excursions on the involved vaccine. There was no additional adverse event (AE) reported. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. devicelotnumber: S037576; expirationdate: 10-APR-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability
Tingling in left hand and foot. Started 1 day after receiving shot and continued for 14 days.
After two minutes post vaccination patient reported feeling extremely anxious, hyperventilating.  Advised to lay in recliner, given fluids and monitored for an extended period.  Vitals 110/82, 76 HR.  After 60 minutes observation patients symptoms resolved and cleared to leave.
Very sore arm; Feeling gross; Suspicion of wrong injection site ("on triceps"); This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Very sore arm), FEELING ABNORMAL (Feeling gross) and INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Suspicion of wrong injection site ("on triceps")) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Very sore arm), FEELING ABNORMAL (Feeling gross) and INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Suspicion of wrong injection site ("on triceps")). At the time of the report, PAIN IN EXTREMITY (Very sore arm), FEELING ABNORMAL (Feeling gross) and INCORRECT ROUTE OF PRODUCT ADMINISTRATION (Suspicion of wrong injection site ("on triceps")) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided.  Based on the current available information and temporal association between the use of the product and the start date of the events, feeling abnormal and pain in extremity, a causal relationship cannot be excluded.  This report also refers to a case of Incorrect route of product Administration for mRNA-1273, lot # 025B21A.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, feeling abnormal and pain in extremity, a causal relationship cannot be excluded.  This report also refers to a case of Incorrect route of product Administration for mRNA-1273, lot # 025B21A.
Severe nausea for 6 hours. A few hours of feeling dizzy and weak and sweaty.
Headache, chills, fever 100.7, fatigue, itchy redness below injection site.
Pt recvd vax & exp serum sickness type react consisting of joint pain, weakness &/or diarrhea; workup has included numerous tests for collagen vascular diseases, has been non-diagnostic;
Aggressive Dry Cough.  Continues to get more aggressive. 1st Dr. visit - 1 round antibiotic / 1 round steroids 2nd Dr. visit - 2 round steroids (different brand) 3rd Dr. visit - medicated inhaler 4th Dr. visit - taking place today (11.10.21)
I had a sore arm that restricted movement, but that left after two days. I had a lot of abdominal pain, nausea, loss of apatite.  I had diarrhea and a headache as well.
day after, started my menstrual cycle even though i already had it a week prior. have now been bleeding for 8 days, extremely heavy. lots of blood clots, soaking through tampons within 30-40 minutes, and having to change my pads every time i stand up
Information has been received concerning a 17 month old male with t-cells, intestinal dysmotility, abnormal IgG levels (not known pre-vaccination), failure to thrive, who on 21-SEP-2007, was vaccinated with VARIVAX. Concomitant vaccination included MMR. On 06-OCT-2007, he had developed 5-6 scattered papules (1-2 vesicles). Diagnostics on 06-Oct-2007 included: blood (CD3-CD4+) helper/inducer T-cell lymphocyte count (29%), serum aspartate aminotransferase test (541), serum alanine aminotransferase test (380), blood helper/inducer cell lymphocyte count (190; 16%), serum immunoglobulin G test 175, and direct fluorescent antibody absorption test (positive) varicella zoster> Subsequently, on 12-OCT-2007, he was hospitalized and therapy with acyclovir was instituted. It was reported that a swab was received 13-Oct-2007, and that the lab had re-read the specimen and reported that the direct fluorescent antibody absorption test was negative for varicella zoster virus. The result of the varicella zoster virus strain identification was vaccine strain. Current patient status was not reported. No product quality complaint was reported. No further information was available. Additional information has been requested.
Approximately 1 1/2 hrs. after receiving H1N1 injectable student reported back to imms area complaining of chest heaviness, no obvious shortness of breath, skin color pale, no cyanosis, sitting up right with out difficulty.  120/64 p. 82. 16, states"I just can't take a deep breath."  Reports participating in gym class with the chest heaviness, and since it did'nt go away student came to be evaluated.  Student's mother notified, student monitored x 20 minutes, symptoms did not  appear to worsen, discharged to parent's care.
1st dose 18jun2018, 2nd 24aug2022; This case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too long in a 59-year-old female patient who received Herpes zoster (Shingrix) (batch number 9CR2S, expiry date 24th September 2023) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on 18th June 2018).   On 24th August 2022, the patient received the 2nd dose of Shingrix. On 24th August 2022, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.       Additional Information: GSK Receipt Date: 25-AUG-2022 Reporter's Comments: The nurse reported that the patient received first dose of Shingrix series on 18th June 2018, and did not receive second dose until 24th August 2022. The reporter did not have lot number/expiration date information for the first dose. Additional Supportive Information: The patient received 2nd dose Shingrix late, more than recommended interval which led to lengthening of vaccination schedule. The reporter consented to follow up.
It began with left upper extremity muscle ache and weakness.  It has been on and off since the time of onset.  Also generalized fatigue and myalgias. Two left suborbital red pustules occured same day.
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown age and genders. The reporter stated that, on an unspecified date, an unknown number of doses of PEDVAXHIB (dose, lot#, expiration dates not provided) that were stored at 48 degrees F for 20 minutes, then exposed to 47 degrees for 9 minutes have been administered. No adverse effects were reported. Follow up information has been received on 22-JUL-2014 from a receptionist. The reporter stated that there were two different lot numbers of PEDVAXHIB that were included in the temperature excursion: Lot # J016188, expiration date: 02-OCT-2016 and lot # J015437, expiration date: 09-OCT-2016. The receptionist did not have any additional information to share. Follow-up information has been received from the registered nurse who provided patients details. This report refers to a 15 months old infant patient of unknown gender. On 20-JUN-2014 the patient was vaccinated with a dose of PEDVAXHIB (dose and route were not reported, lot# J016188, expiration date 02-OCT-2016) that was improperly stored. No adverse effect were reported. This is the one of several reports received from the same reporter. Additional information is not expected.
COUGH., MYALGIAS, FATIGUE, WEAKNESS, POOR APPETITE AND FEVER
Pt presented two days after getting a shingles vaccine with an elevated circular red area where the vaccine was admin. MD prescribed MEDROL dose pack.
Patient tested positive for COVID-19. Patient was hospitalized and he is fully vaccinated. Patient began experiencing severe fatigue and a fever of 102.5 approximately 2 weeks ago. Patient was hospitalized from 8/5-8/8 after going into urgent care to get tested.
Patient had heavy bruising from injection site to below elbow. The bruising was still visible at the time of the second dose four weeks later.
Redness began around injection site on morning of 1/26/21 with knot below skin. Sitewas warm to touch and very sore. This has continued and then itching to site began this morning upon awakening at 5am. Throughout day the redness at site is now growing larger andhas spread fewinches below site and itching worse.